Neonatal jaundice is a common clinical condition in the neonatal age, most frequently in the first week of life. It manifests due to different physiological and pathological phenomena related to the metabolism process of bilirubin. Data from Saudi Arabia identifies physiological jaundice as the most common cause in the region, followed by indirect hyperbilirubinemia, early onset jaundice, direct hyperbilirubinemia, and persistent hyperbilirubinemia jaundice. Early recognition and prompt treatment of the condition are crucial to evade serious complications and promote the neonate’s health. The present study reviewed the literature searching for the etiology of neonatal jaundice, diagnosis, risk factors, and management of this disease. PubMed database was used for articles selection, and gathered papers had undergone a thorough review. Jaundice in newborns is rather common and can be caused by a variety of factors. Many doctors believe that infant jaundice is a minor condition, but it is a severe condition that can cause irreversible brain damage. Everyone in the field of neonatology should be aware of this. Furthermore, parent education is critical and to those in the field of neonatology.
1. Bhutani VK, Zipursky A, Blencowe H, Khanna R, Sgro M, Ebbesen F, et al. Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. Pediatr Res. 2013;74(1):86-100. doi:10.1038/pr.2013.208
2. Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. Lancet (London, England). 2008;371(9607):135-42. doi:10.1016/S0140-6736(08)60106-3
3. Burke BL, Robbins JM, Mac Bird T, Hobbs CA, Nesmith C, Tilford JM. Trends in hospitalizations for neonatal jaundice and kernicterus in the United States, 1988–2005. Pediatrics. 2009;123(2):524-32. doi:10.1542/peds.2007-2915
4. Alkhotani A, Eldin EE, Zaghloul A, Mujahid S. Evaluation of neonatal jaundice in the Makkah region. Sci Rep. 2014;4(1):4802. doi:10.1038/srep04802
5. Mitra S, Rennie J. Neonatal jaundice: aetiology, diagnosis, and treatment. Br J Hosp Med (Lond). 2017;78(12):699-704. doi:10.12968/hmed.2017.78.12.699
6. Boyd S. Treatment of physiological and pathological neonatal jaundice. Nurs Times. 2004;100(13):40-3.
7. Bratton S, Cantu RM, Stern M. Breast Milk Jaundice. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
8. Mishra S, Agarwal R, Deorari AK, Paul VK. Jaundice in the newborns. Indian J Pediatr. 2008;75(2):157-63. doi:10.1007/s12098-008-0024-7
9. Pegoraro V, Urbinati D, Visser GH, Di Renzo GC, Zipursky A, Stotler BA, et al. Hemolytic disease of the fetus and newborn due to Rh (D) incompatibility: A preventable disease that still produces significant morbidity and mortality in children. PLoS One. 2020;15(7):1-11. doi:10.1371/journal.pone.0235807
10. Akgül S, Korkmaz A, Yiğit S, Yurdakök M. Neonatal hyperbilirubinemia due to ABO incompatibility: does blood group matter? Turk J Pediatr. 2013;55(5):506-9.
11. D’Silva S, Colah RB, Ghosh K, Mukherjee MB. Combined effects of the UGT1A1 and OATP2 gene polymorphisms as a major risk factor for unconjugated hyperbilirubinemia in Indian neonates. Gene. 2014;547(1):18-22. doi:10.1016/j.gene.2014.05.047
12. Kaplan M, Wong RJ, Stevenson DK. Hemolysis and Glucose-6-Phosphate Dehydrogenase Deficiency-Related Neonatal Hyperbilirubinemia. Neonatology. 2018;114(3):223-5. doi:10.1159/000489820
13. Moiz B, Nasir A, Khan SA, Kherani SA, Qadir M. Neonatal hyperbilirubinemia in infants with G6PD c.563C > T Variant. BMC Pediatr. 2012;12(1):126. doi:10.1186/1471-2431-12-126
14. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297-316. doi:10.1542/peds.114.1.297
15. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or =35 weeks’ gestation: an update with clarifications. Pediatrics. 2009;124(4):1193-8. doi:10.1542/peds.2009-0329
16. Bhatt DR, Kristensen-Cabrera AI, Lee HC, Weerasinghe S, Stevenson DK, Bhutani VK, et al. Transcutaneous bilirubin meter use and practices surrounding jaundice in 150 California newborn intensive care units. J Perinatol. 2018;38(11):1532-5. doi:10.1038/s41372-018-0154-3
17. Frank JE. Diagnosis and management of G6PD deficiency. Am Fam Physician. 2005;72(7):1277-82.
18. Woodgate P, Jardine LA. Neonatal jaundice: phototherapy. BMJ Clin Evid. 2015;2015.
19. Bujandric N, Grujic J. Exchange transfusion for severe neonatal hyperbilirubinemia: 17 years’ experience from Vojvodina, Serbia. Indian J Hematol Blood Transfus an Off J Indian Soc Hematol Blood Transfus. 2016;32(2):208-14. doi:10.1007/s12288-015-0534-1
20. Cortey A, Elzaabi M, Waegemans T, Roch B, Aujard Y. Efficacy and safety of intravenous immunoglobulins in the management of neonatal hyperbilirubinemia due to ABO incompatibility: a meta-analysis. Arch Pediatr. 2014;21(9):976-83. doi:10.1016/j.arcped.2014.02.005
21. Kaabneh MA, Salama GS, Shakkoury AG, Al-Abdallah IM, Alshamari A, Halaseh RA. Phenobarbital and phototherapy combination enhances decline of total serum bilirubin and may decrease the need for blood exchange transfusion in newborns with isoimmune hemolytic disease. Clin Med Insights Pediatr. 2015;9:67-72. doi:10.4137/CMPed.S2490
Copyright © 2024 Archives of Pharmacy Practice. Authors retain copyright of their article if they are accepted for publication.
Developed by Archives of Pharmacy Practice
